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The complement system is a major effector of humoral immunity and natural immunity. The complement system
has three independent pathways of complement activation: a classical pathway, an alternative pathway, and a
lectin pathway. These pathways converge to a common pathway that activates C3. This pathway also leads to the
formation of various bioactive molecules such as C5a and the formation of membrane attack complex on the
surface of target cells. In the past, the only preparations with anti-complementary action were C1 inhibitors
(C1-INH), but an anti-C5 monoclonal antibody (eculizumab) appeared a few years ago, and this antibody has
yielded encouraging results. In addition, a C5a receptor (C5aR) antagonist is in the clinical trial phase, and this
antagonist should also prove efficacious. Anti-complement agents have garnered attention as a new treatment
strategy for refractory inflammatory diseases.
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The complement system consists of more than 30 pro-
teins. These proteins are activated sequential order in a
cascade that produces a variety of molecules that maintain
homeostasis in the body by, for example, defending the
body from infection. Complement activation results in the
formation of membrane attack complex (MAC), and this
complex produces holes in the cell membrane, causing
the destruction of target cells. Complement fragments
such as C3a, C4a, and C5a trigger inflammation as ana-
phylatoxins and chemotactic factors, and abnormal com-
plement activation leads to various inflammatory diseases
[1, 2].
Over the past few years, a monoclonal antibody
against complement component C5 (eculizumab) has
been approved as a treatment for paroxysmal noctur-
nal hemoglobinuria and atypical hemolytic uremic
syndrome (aHUS), and this antibody has yielded en-
couraging results [3, 4]. Eculizumab binds to C5 and
thus inhibits the cleavage of C5 into C5a and C5b,
but its principal action is presumably by inhibiting* Correspondence: horiuchi@beppu.kyushu-u.ac.jp
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stated.the formation of C5b, which precludes the formation
of MAC [5]. CCX168 was recently developed to inhibit
inflammation caused by C5a. CCX168 is an orally admin-
istered C5a receptor antagonist. In a phase II clinical trial
of CCX168 to treat anti-neutrophil cytoplasmic antibody
(ANCA)-associated renal vasculitis (AARV), administra-
tion of CCX168 (+cyclophosphamide) was as efficacious
as or more efficacious than the standard treatment (high-
dose prednisolone + cyclophosphamide) [6, 7]. CCX168
has garnered attention as a potential replacement for
corticosteroids, so CCX168 holds promise.
This paper outlines the mechanisms of complement
activation. This paper then describes anti-complement
agents that are being put to practical use. Last, this
paper describes a C5a receptor antagonist that is in
development.Mechanisms of complement activation
Complements are activated in three independent path-
ways: a classical pathway, an alternative pathway, and a
lectin pathway (Fig. 1). These three pathways ultimately
converge to a common pathway where they form a
crucial enzyme known as C3 convertase. The classical
pathway is triggered when the complement C1 complexs This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
u give appropriate credit to the original author(s) and the source, provide a link
e if changes were made. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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Fig. 1 Complement activation. Three pathways, i.e., classical, lectin, and alternative pathways, are independently activated to form C3 convertase.
The activation of this cascade culminates in the generation of various fragments derived from complement proteins and the formation of membrane
attack complex (MAC). The former acts as potent mediators of inflammation by binding to their receptors on the cell surface, while the latter is
comprised of C5b, C6, C7, C8, and multiple copies of C9 that generate lytic pores in cellular membranes
Horiuchi and Tsukamoto Inflammation and Regeneration  (2016) 36:11 Page 2 of 5binds to antibodies that are bound to antigens. Once C1
is activated, C4 and then C2 are activated. In the
process, C4b and C2a are produced, and these two frag-
ments combine to form C3 convertase. The lectin path-
way is triggered when mannose-binding lectin (MBL)
recognizes mannose or other carbohydrate sugar resi-
dues on the surface of pathogens. Once MBL-associated
serine protease (MASP) is activated, C4 and then C2 are
activated. Like in the classical pathway, C4b2a functions
as C3 convertase in the lectin pathway. In the alternative
pathway, complement factor D is directly activated by
the surface of foreign particles. Once factor D is acti-
vated, factor B and then complement component C3 are
activated. In the process, C3b and Bb are produced, and
these two fragments combine to form C3bBb. C3bBb
functions as C3 convertase on the surface of foreign
substances [1, 2].
C3 is broken down into C3a and C3b by C3 convertase.
C3b binds to C3 convertase to form C5 convertase, and
C5 is broken down into C5a and C5b. C3a, C4a, and C5a
function as potent mediators of inflammation, binding to
receptors on the surface of lymphocytes, macrophages,
and endothelial cells. Other products of the cleavage of
these components have biological functions. C5b binds to
the surface of foreign particles. C5b triggers the assembly
of complement components C6 to C9 into MAC, which
destroys foreign particles [1, 2].
Molecularly targeted therapies with antibodies are yield-
ing dramatic results in the treatment of rheumatoid arth-
ritis (RA) and malignancies. Complement activation by
the antibodies themselves is crucial to their action [8, 9].Complement-targeting drugs that are being put
to practical use
Complement activation serves to eliminate pathogens,
but abnormal activation is heavily involved in the path-
ology of various conditions. As of today (February 2016),
two drugs targeting specific complement components
are being put to practical use. One is a drug that supple-
ments a deficient complement while the other inhibits a
complement.
1. C1 inhibitor (C1-INH) (Berinert®)
Hereditary angioedema (HAE) is due to a deficiency in
the inhibitor of complement component C1 (C1-INH). A
C1-INH has been refined from human plasma to supple-
ment the lacking C1-INH. HAE is an autosomal dominant
genetic condition in which an abnormality in the C1-INH
gene causes a deficiency of C1-INH that in turn causes
transient edema (angioedema) at various sites. The epi-
demiology of HAE in Japan is unclear, but studies in
Europe and the USA estimate that HAE affects 1 in every
50,000 people. If acute edema appears in the eyelids and
lips, it can also appear in the bowel and the larynx. Edema
of the bowel causes intense abdominal pain, and edema of
the larynx can cause asphyxia. Despite its rarity, these
symptoms of HAE mean that it must be identified. During
an episode of edema, administration of C1-INH can cause
the episode to promptly end. Information on diagnosis
and treatment of HAE can be found in the guidelines on
hereditary angioedema from the Japanese Association for
Complement Research [10].
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(Soliris®)
Eculizumab is a humanized anti-C5 monoclonal anti-
body that binds to the α chain of C5. This prevents C5
from being cleaved into C5a and C5b by C5 convertase.
As of February 2016, eculizumab is indicated for parox-
ysmal nocturnal hemoglobinuria (PNH) and atypical
hemolytic uremic syndrome (aHUS), but a prospective
clinical study is underway to expand its indications to
include age-related macular degeneration, myasthenia
gravis, optic neuritis, and preventing rejection of a kid-
ney transplant [11].
PNH is a progressive hematologic disorder with a
triad of features: complement-mediated intravascular
hemolysis, bone marrow failure, and thrombosis. Japan is
estimated to have a population of around 430 patients
with PNH. The condition is caused by clonal expansion of
hematopoietic stem cells with an acquired mutation in the
PIG-A gene. In PNH, blood cells lack several types of
proteins on their surface because the cells lack an anchor,
glycosylphosphatidylinositol (GPI), to hold the proteins to
that surface. These missing proteins include CD55 (a
decay-accelerating factor, or DAF) and CD59 (a homolo-
gous restriction factor, or HRF) that would be present on
the surface of various cells, such as red blood cells, to
protect them from complement attack [12].
aHUS is defined as a condition with a triad of features:
hemolytic anemia, thrombocytopenia, and acute renal
insufficiency. The atypical form of aHUS is not associ-
ated with Shiga toxin, and the condition is not throm-








Fig. 2 Activation of C5 by C5 convertase leads to the generation of C5a an
activities. C5b initiates the formation of MAC, which lyses cells as well as trextremely poor prognosis. aHUS due to genetic comple-
ment abnormalities can be treated with eculizumab.
When surplus complement is activated in conjunction
with abnormalities in various molecules involved in the
alternative pathway of complement activation, vascular
endothelial cells and platelets are activated and aHUS
develops. Administration of eculizumab results in an
improved prognosis for patients with aHUS [13]. A
study has also suggested that eculizumab would be
efficacious in treating HUS associated with Shiga toxin
and TTP as well [14].
Eculizumab inhibits two complement functions, the
anaphylatoxic action of complement component C5a and
interaction with C5b that leads to the formation of MAC.
Inhibition of the formation of MAC increases a patient’s
susceptibility to a meningococcal infection, so caution is
required. Thus, vaccination with a meningococcal vaccine
prior to administration of eculizumab is recommended.
Moreover, vaccination of small children with a pneumo-
coccal vaccine and an influenza type B vaccine is also
recommended.
Complement C5a receptor antagonists
Attempts have long been made to develop inhibitors of
complement C5 activation besides eculizumab [15]. These
inhibitors target factors upstream of C5, including (in
order) C5 convertase, complement components C5, C5a,
and C5b, and C5a receptor (Fig. 2). Various types of
antibodies and compounds such as peptides or non-
peptides have actively been developed, and these sub-
stances act as inhibitors of complement components C5
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ing various inflammatory diseases involving complements.
There is interest in the efficacy of these anti-complement
agents on RA. In fact, numerous findings have suggested a
relationship between RA and C5 and C5a receptors. C5a
levels in synovial fluid are elevated in patients with RA [16],
a genome-wide association study (GWAS) indicated that
the TRAF1-C5 region is related to RA in humans [17, 18],
numerous animal models have indicated that C5 is a gene
responsible for causing arthritis [19, 20], and C5 and C5a
receptor knockout mice are resistant to arthritis [21, 22].
However, clinical trials indicated that eculizumab (a hu-
manized anti-C5 monoclonal antibody) and PMX53 and
MP-435 (C5a receptor antagonists) had little efficacy in
treating RA [23, 24].
Research has also suggested that complements are
involved in causing ANCA-associated vasculitis (AAV)
in humans. Patients with active AAV have significantly
elevated C5a levels in plasma and urine in comparison
to healthy people and patients with inactive AAV [25].
Bb levels in plasma are correlated with the disease activ-
ity of AAV in humans [26]. In a mouse model of nephritis
induced with myeloperoxidase anti-neutrophil cytoplasmic
antibody (MPO-ANCA), knocking out complement factor
B and complement component C5 resulted in the absence
of nephritis [27]. In light of these findings, researchers con-
ceived of a model in which neutrophils stimulated by ANCA
cause the release of substances that activate the alternative
pathway of complement activation [27]. This activation re-
sults in the activation of complement factor B. Complement
activation proceeds in association with the generation of
C5a and MAC, producing nephritis. In fact, administration
of an anti-C5 antibody in the mouse model of nephritis in-
duced with MPO-ANCA almost entirely inhibited nephritis
[28]. Knocking out the C5a receptor in the mouse model of
nephritis induced with MPO-ANCA inhibited nephritis
[29]. In addition, knocking in the human C5a receptor pro-
duced nephritis in mice [29]. When CCX168 (a C5a recep-
tor antagonist) was administered in the mouse model of
nephritis induced with MPO-ANCA, nephritis was inhibited
in a dose-dependent manner [29]. Thus, the alternative
pathway of complement activation is activated in MPO-
ANCA-associated nephritis, and a C5a receptor antagonist
may be efficacious in treating that nephritis.
The C5a receptor antagonist CCX168 was efficacious
in mice, and the C5aR inhibitor on Leukocytes Explora-
tory ANCA-associated Renal Vasculitis (CLEAR) trial
was conducted to determine if CCX168 would be simi-
larly efficacious in humans [6, 7]. This trial was a ran-
domized, double-blind, placebo-controlled phase II trial
in which the C5a receptor antagonist CCX168 was orally
administered to patients with ANCA-positive granulo-
matosis with polyangiitis (GPA), microscopic polyangiitis
(MPA), or renal limited vasculitis. Patients were dividedinto three groups, with one receiving the standard treat-
ment (cyclophosphamide 15 mg/kg IV pulses every 2–
3 weeks + high-dose prednisolone 60 mg/day + a pla-
cebo; n = 9), one receiving CCX168 and prednisolone
(cyclophosphamide 15 mg/kg IV pulses every 2–3 weeks
+ low-dose prednisolone 20 mg/day + 30 mg CCX168
twice daily; n = 8), and another receiving CCX168 but
not prednisolone (cyclophosphamide 15 mg/kg IV pulses
every 2–3 weeks + no prednisolone + 30 mg CCX168
twice daily; n = 8). The efficacy of each treatment was
compared after 12 weeks. Administration of CCX168
was as efficacious as or more efficacious at inhibiting
nephritis as the standard treatment. Moreover, CCX168
was efficacious in treating forms of disease activity
besides nephritis. Patients receiving CCX168 were able
to tolerate the drug, and they suffered no serious un-
anticipated adverse events. In addition to the CLEAR
trial, the Clinical ANCA Vasculitis Safety and Efficacy
Study of Inhibitor of C5aR (CLASSIC) trial is underway.
This randomized, double-blind, placebo-controlled
phase II trial intends to determine if CCX168 will allow
a lower dose or discontinuation of corticosteroids for
patients with AAV. Phase II pilot studies of CCX168 to
treat aHUS and immunoglobulin A (IgA) nephropathy
are also underway.
Eculizumab is an anti-C5 antibody, but C5a receptor
antagonists target C5a alone and do not inhibit MAC, so
those antagonists may lessen risk of an infection with a
pathogen such as Neisseria meningitidis seen with eculi-
zumab. However, caution is needed since the C5a recep-
tor is involved in maintaining homeostasis in the body.
In specific terms, the C5a receptor is expressed not only
by hematopoietic cells but also by various non-immune
cells, such as vascular endothelial cells, liver cells, kidney
cells, lung cells, spleen cells, and cells of the gastrointes-
tinal tract [30]. Long-term studies are needed to deter-
mine if blocking the C5a receptor has unanticipated
effects.
Conclusions
Research has revealed that several conditions respond to
eculizumab and new attention has focused on eculizu-
mab in relation to the treatment of conditions involving
the complement system. This paper has described mole-
cules functioning in the latter stages of complement
activation, such as C5 and C5a receptors, but inhibitors
of molecules functioning in the earlier stages of comple-
ment activation, such as complement factor D, comple-
ment factor B, properdin, MASP, and C3 convertase, are
also being developed [11, 31]. These inhibitors may allow
regulation of various steps in the complement system.
Thus far, few attempts have been made to control disease
by inhibiting complements, so those attempts hold prom-
ise as a new treatment strategy.
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